How to Treat Post-Inflammatory Hyperpigmentation

Post-inflammatory hyperpigmentation, commonly called PIH, is the dark discoloration left behind after your skin heals from an injury or inflammation. It is one of the most common reasons people with medium to dark skin tones visit a dermatologist, and it can linger for months or even years after the original problem has cleared. The condition is not dangerous, but it is frustrating, frequently more bothersome than whatever caused it in the first place, and the science behind treating it has evolved considerably in recent years.

What Triggers It

Almost any event that inflames or damages the skin can leave a dark mark behind. Acne is probably the single most common trigger, but eczema, psoriasis, bug bites, burns, cuts, and even cosmetic procedures like chemical peels or laser treatments can do it too.¹ The underlying process is straightforward: when skin cells are injured, they release inflammatory signals. Those signals stimulate melanocytes, the cells that produce pigment, to ramp up melanin production. The extra melanin gets deposited into surrounding skin cells or drops deeper into the tissue, and what you see on the surface is a flat, darkened patch in the shape of whatever the original insult looked like.

The intensity of the mark tends to track with the severity of the inflammation. A single shallow pimple might leave a faint brown spot that fades in weeks; a deep cystic acne lesion or a second-degree burn can leave a much darker patch that persists far longer. Picking at or squeezing acne worsens the odds of PIH because the mechanical trauma adds another layer of inflammation on top of the breakout itself.

Why Darker Skin Tones Are Hit Harder

PIH can technically happen to anyone, but the frequency and severity are dramatically skewed toward people with more melanin in their skin. A systematic review of treatment studies found that roughly 40% of the patients enrolled had Fitzpatrick skin type IV, about 34% had type V, and 20% had type III, with only about 6% representing the darkest category, type VI.² Those proportions reflect who shows up for treatment, but the pattern is consistent across studies: people with darker skin experience PIH with greater frequency and severity.³

The reason comes down to melanocyte biology. Darker skin has melanocytes that are already more active and produce larger, more heavily pigmented melanin granules. When inflammatory signals hit those melanocytes, the response is amplified. The upshot is that a mild inflammatory event that would leave no visible trace on very fair skin can leave a conspicuous dark patch on brown or black skin. This also means that some of the treatments used for PIH, if they cause irritation themselves, risk triggering a new round of hyperpigmentation, a frustrating catch-22 that shapes treatment choices.

Epidermal Versus Dermal PIH

Not all PIH behaves the same way, and one of the most important distinctions is how deep the excess pigment sits. Histological studies have identified two clear patterns: an epidermal form, where extra melanin accumulates in the upper layer of skin, and a dermal form, where pigment drops into the deeper dermis.⁴ The distinction matters because it predicts how the mark will behave over time and how well it responds to treatment. Epidermal PIH tends to look tan to dark brown and fades more readily. Dermal PIH often appears blue-gray or slate-colored and can persist for years because the pigment is trapped deeper, out of reach of the skin’s normal turnover cycle.⁵

A dermatologist can sometimes estimate which type you have by color alone: brown shades lean epidermal, blue-gray leans dermal. A Wood’s lamp exam, which uses ultraviolet light, can help too, since epidermal melanin becomes more visible under UV while dermal melanin does not enhance as much. The clinical takeaway is that if your marks are blue-gray and have been static for months, topical creams alone may not resolve them, and you may need to adjust your expectations or explore other options.

How PIH Differs From Melasma

PIH and melasma both present as dark patches, and they often get confused. The key difference is pattern and cause. Melasma typically appears as symmetrical patches on the forehead, cheeks, and chin, concentrated in sun-exposed areas, and it is driven primarily by hormonal factors and ultraviolet exposure. PIH, by contrast, appears irregularly, in whatever location the triggering inflammation occurred.⁶ If you had a cluster of acne on your jawline, the PIH will be on your jawline. If you scratched a bug bite on your forearm, the dark spot will be there.

This matters because the two conditions overlap in some treatment approaches but diverge in others. Melasma tends to be chronic and recurrent in ways that PIH is not. PIH, by definition, has a discrete cause, and once that cause is controlled, the marks will eventually fade even without active treatment, though “eventually” can mean a very long time. Many people have both conditions simultaneously, which complicates things because a treatment that is excellent for one can be insufficient for the other.

First-Line Topical Treatments

The standard approach to PIH starts with topical agents that slow melanin production. The most studied is hydroquinone, which works by inhibiting tyrosinase, the enzyme melanocytes need to make melanin. It is typically used at concentrations of 2% over the counter or 4% by prescription and is recommended for short-term courses because prolonged use at high concentrations carries a small risk of a paradoxical darkening called ochronosis.⁷ Other tyrosinase inhibitors with evidence behind them include azelaic acid, kojic acid, arbutin, and certain licorice-derived extracts.⁸

Azelaic acid deserves special mention for people whose PIH stems from acne, because it pulls double duty. It inhibits tyrosinase to lighten dark spots, but it also has antimicrobial and anti-inflammatory properties that help control the acne itself.⁹ It is generally well tolerated, with mild irritation and itching being the most common complaints, making it a good starting point for people with sensitive skin who struggle with stronger products.

Topical retinoids, derivatives of vitamin A, are another cornerstone. They do not directly block tyrosinase, but they speed up epidermal turnover and interfere with the transfer of melanin granules from melanocytes to surrounding skin cells. They also tamp down inflammation through several pathways, including reducing cytokine release.¹⁰ The catch is that retinoids frequently cause redness, peeling, and irritation during the first few weeks of use, and on darker skin, that irritation itself can temporarily worsen PIH before improving it. Starting with a low concentration and applying it every other night helps minimize this initial flare.

Chemical Peels

Chemical peels accelerate the shedding of pigmented surface cells, essentially forcing the epidermis to turn over faster. Among the various acids used, salicylic acid and glycolic acid have the strongest evidence specifically for PIH.¹¹ Salicylic acid is oil-soluble, which lets it penetrate pores more effectively, making it a natural choice when acne is part of the picture. Glycolic acid is water-soluble and works more on the skin’s surface, and it has been studied in combination with topical regimens.

A comparative study in patients with dark skin found that combining glycolic acid peels with a topical lightening regimen produced significantly better results than the topical regimen alone, with measurable improvement at 12 weeks that continued widening through 21 weeks.¹² Side effects occurred in both groups but were mild enough that no one dropped out. The important caveat with peels, especially at higher concentrations, is the same irritation paradox that applies to retinoids: if the peel is too aggressive or the recovery is poorly managed, you can trigger new PIH on top of the old.

Sunscreen and Prevention

Ultraviolet light stimulates melanocytes regardless of whether any inflammation is present, and on skin that is already primed by a recent inflammatory episode, UV exposure can darken existing PIH and slow its resolution. Daily broad-spectrum sunscreen is arguably the single most important intervention for anyone dealing with PIH, and it is often the piece that gets the least attention.

There is also growing interest in protection beyond traditional UV. Visible light, particularly in the blue portion of the spectrum, can induce skin pigmentation independently of UV, and this effect is more pronounced in darker skin tones. A clinical study found that sunscreens containing newer broad-spectrum filters significantly reduced blue-light-induced skin pigmentation after a single exposure.¹³ Tinted mineral sunscreens that contain iron oxides also block visible light and are worth considering if your PIH is stubborn or if you spend long hours near screens and windows.

On the prevention front, a systematic review examined whether proactive strategies could stop PIH from forming after procedures like laser skin resurfacing. In one set of studies, patients who applied a sunscreen formulated with anti-inflammatory and antioxidant ingredients daily for about a month after treatment had a 100% success rate in preventing PIH over a two-month follow-up period.¹⁴ That is a small dataset and a specific context, but it underscores that diligent sun protection and anti-inflammatory care immediately after an injury or procedure may prevent PIH from developing in the first place, rather than treating it after the fact.

Newer and Off-Label Options

Tranexamic acid, a drug traditionally used to control bleeding, has emerged as one of the more promising newer tools for PIH. It works through a different mechanism from tyrosinase inhibitors: it blocks the interaction between skin cells and melanocytes that drives pigment production in inflamed tissue. A systematic review of its use in PIH found it had been studied via oral, topical, and intradermal injection routes. Almost all of the reviewed studies supported its ability to accelerate clearance of hyperpigmentation, with topical and intradermal routes being favored because they carried fewer systemic side effects than oral dosing.¹⁵

Some dermatologists have gone further, using tranexamic acid not just to treat existing PIH but to prevent it in high-risk patients. One clinical group reported using it off-label in roughly 82 patients before procedures like microneedling, cryotherapy, chemical peels, and laser treatments, as well as after acute injuries like burns and abrasions, with success in preventing PIH from developing.¹⁶ This prophylactic use is still considered off-label and is not yet standard practice, but it reflects the growing clinical interest in getting ahead of PIH rather than chasing it after it appears.

Another newer agent gaining traction is thiamidol, a tyrosinase inhibitor available in over-the-counter skincare products in some markets. In a controlled study, skin sites treated with thiamidol became significantly lighter than untreated sites within two weeks, and improvements continued over a 12-week treatment period as confirmed by device measurements, expert assessment, and patient self-ratings.¹⁷ It is not as extensively studied as hydroquinone, but its availability without prescription and apparent tolerability make it an appealing option for people who want to avoid the restrictions associated with hydroquinone use.

The Emotional Toll

One of the least discussed aspects of PIH is how much it affects people psychologically. Because the dark marks sit right on the surface, in locations often caused by acne on the face, the impact on self-image can be considerable. A study comparing acne patients who developed PIH with those who had acne alone found that the PIH group reported significantly worse quality-of-life scores. Sixty percent of patients with PIH said it had a “very marked” impact on at least one aspect of their daily life, compared to none of the acne-only patients.¹⁸ The impairment was especially pronounced in social and emotional functioning.

A study of university students in Nigeria found that increasing PIH severity was significantly associated with worsening quality of life and higher levels of depressive symptoms. While the average depression score was low, roughly a fifth of participants had moderate depressive symptoms, and a small percentage had severe depression.¹⁹ These findings matter because PIH is often dismissed as a purely cosmetic concern, which can make patients feel their distress is not taken seriously. For many, the dark marks are the primary reason they seek dermatologic care, not the acne itself.

How Long It Lasts Without Treatment

One of the most common questions is how long PIH takes to fade on its own. The honest answer is that the range is enormous. Superficial epidermal PIH can resolve in a few months, especially in lighter skin tones where melanocyte activity is lower and epidermal turnover naturally clears the excess pigment. Dermal PIH, on the other hand, can persist for years and may never fully resolve without intervention. Most cases of moderate facial PIH in darker skin fall somewhere in the range of six months to over two years of gradual fading, assuming the original trigger has been controlled and the person is using sunscreen consistently.

The biggest factor slowing resolution is ongoing inflammation. If the underlying cause, whether acne, eczema, or another condition, is still active, new PIH keeps forming even as older marks fade. This is why dermatologists emphasize controlling the primary condition as step one. Treating dark marks while new pimples are still arriving is like mopping a floor with the faucet running.

Hydroquinone Safety in Context

Hydroquinone occupies an unusual place in the PIH treatment landscape. It remains the most effective single topical agent for lightening hyperpigmented skin, yet it has attracted regulatory scrutiny and public anxiety, particularly after the U.S. FDA proposed removing it from over-the-counter availability in 2006. Much of the concern centers on ochronosis, the paradoxical blue-black darkening that can develop with chronic use. A literature review that examined the actual incidence of this complication found only 22 reported cases in the United States over more than 50 years, across a body of clinical research involving over 10,000 carefully supervised exposures.²⁰

The reported cases of ochronosis have generally involved very high concentrations used for prolonged periods, often in products obtained outside regulated markets. At the standard 2-4% concentrations used in dermatologic practice for defined treatment courses of three to six months, the risk appears to be exceedingly small. Still, the concern has had a real effect on access: in several countries, hydroquinone is now prescription-only or banned outright. The practical result is that some people turn to unregulated products with unknown concentrations, which ironically increases the very risk the regulations were meant to reduce. If you use hydroquinone, getting it through a dermatologist or a regulated pharmacy and sticking to a defined treatment period remains the safest approach.